R&D Pipeline for New Medicine
R&D_Pipeline
( US, China, Japan )| Therapeutic Area | Project code | Indication | Discovery | Preclinical | Phase1 | Phase2 | Phase3 | BLA/NDA Review | Partners |
|---|---|---|---|---|---|---|---|---|---|
| Immunology | HL161 (batoclimab) | Myasthenia gravis (MG) |
US/EU |
(US/EU/Japan)
(China) |
|||||
| Japan | |||||||||
| China | |||||||||
| Thyroid eye disease (TED) |
US/EU |
(US/EU/Japan)
(China) |
|||||||
| Japan | |||||||||
| China | |||||||||
| Warm autoimmune hemolytic anemia (WAIHA) |
US/EU |
(US/EU) |
|||||||
| Neuromyelitis optica (NMOSD) |
China |
(China) |
|||||||
| Immune thrombocytopenia (ITP) |
China |
(China) |
|||||||
| Grave's Disease (GD) |
US/EU |
(US/EU) |
|||||||
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
US |
(US/EU) |
|||||||
| Oncology |
HL186 Anti-TIM3 Ab |
Immuno-oncology | US |
|
|||||
|
HL187 Anti-TIGIT Ab |
Immuno-oncology | US |
|
||||||
| Ophthalmology |
HL036 (tanfanercept) |
Dry eye disease (DED) | US |
|
|||||
| China | |||||||||
|
HL189 (tanfanercept) |
Non-Infectious uveitis (NIU) | US | |||||||
| Neurology |
HL192 (ATH399A) |
Parkinson’s Disease | US |
|